Dr. Robert W. Weaver, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of South Florida College of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 757
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: University of South Florida College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME87855 -
Hematology (Internal Medicine) Physician
FL license ME87855
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Josephs Hospital Tampa, FL
- Adventhealth Tampa Tampa, FL
- Adventhealth Wesley Chapel Wesley Chapel, FL
Medical groups
- Florida Cancer Specialists and Research Institute, LLC (498 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 757
- Services billed
- 128,944
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 28,050 | 34 |
| Injection, iron sucrose, 1 mg | 13,100 | 27 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 5,725 | 45 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 5,515 | 59 |
| Injection, denosumab, 1 mg | 3,360 | 28 |
| Injection, aprepitant, 1 mg | 3,120 | 11 |
| Injection, ferric derisomaltose, 10 mg | 2,800 | 20 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,274 | 581 |
| Insertion of needle into vein for collection of blood sample | 1,264 | 572 |
| Injection of drug or substance under skin or into muscle | 718 | 175 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Tampa, FL | 202 |
| Eliquis (apixaban) Other prescribers in Tampa, FL | 78 |
| Ondansetron Hcl Other prescribers in Tampa, FL | 58 |
| Exemestane | 40 |
| Tramadol Hcl Other prescribers in Tampa, FL | 30 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Tampa, FL | 29 |
| Revlimid (lenalidomide) | 27 |
| Prochlorperazine Maleate Other prescribers in Tampa, FL | 27 |
| Lorazepam Other prescribers in Tampa, FL | 26 |
| Warfarin Sodium Other prescribers in Tampa, FL | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 35 companies reported 182 payments worth $5,678 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $525 |
|---|---|
| Daiichi Sankyo Inc. | $482 |
| Gilead Sciences, Inc. | $449 |
| Tersera Therapeutics LLC | $357 |
| Pfizer Inc. | $356 |
| Celgene Corporation | $312 |
| Novartis Pharmaceuticals Corporation | $295 |
| Syndax Pharmaceuticals, Inc. | $294 |
| Food and Beverage | $5,678 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $220,808 in research payments for these studies, mostly to the institutions running them.
- A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals Inc. - Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Mirati Therapeutics, Inc. · Active, not recruiting · NCT04793958 - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Aveo Pharmaceuticals, Inc. · Completed · NCT04987203 - A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy f…
AstraZeneca Pharmaceuticals LP - Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients
Genentech, Inc. - A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP - SERENA-2 A Randomised Open-Label Parallel-Group Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer
AstraZeneca UK Limited - SERENA-2 A Randomised Open-Label Parallel-Group Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.